Our sustained investments in differentiated chemistry platforms, advanced R&D capabilities, and customer partnerships are translating into tangible business opportunities. What began as capability creation is now progressing into commercialisation, with our pipeline advancing from development programmes to confirmed opportunities.

Our CDMO platform is scaling across Agro, Pharma, and Semiconductor applications, while our Fine Chemicals portfolio continues to expand across Pyridine derivatives, Diketene derivatives, and Personal Care applications, strengthening our presence in high-value specialty segments.